Deborah A. O’Neil

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

Leap Confronting Conflict operates as a non-profit organization that provides inspirational conflict management training and support to young people and the professionals working with them. The company was founded on September 8, 1998 and is headquartered in London, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.